Icon

Avandamet - (500mg; EQ 1,2,4mg Base: 1gm; EQ 2,4mg BASE, Tablet)

Rosiglitazone Maleate and Metformin Hydrochloride SB PHARMCO
500mg; EQ 1,2,4mg Base: 1gm; EQ 2,4mg BASE, Tablet
Less Than $1000 mn
Less Than 5
Less Than 5
None None
None None
Indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus for whom all other oral antidiabetic agents, in monotherapy or in combination, do not result in adequate glycemic control or are inappropriate
Yes
**** ** *** ***** ** **** *** **** ** *** *** **** ** *** ******* **** *** ********* ******* * **********. ********* ** *** ***** ** ********** **** *** ***** *** ** ****** **** *** ******* ******** ** *******, ********* *** ********* **** ******* **** ** *** ***** ******* ****. ***** ***** ** *** ********** ****** ************.
Avandamet Patent 1 Patent 2
**** ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ *** **** **** ******* ******** ************ *** ** ******
  1. ***, **** : *** ***** * **** ******* **** ** **** *** ***** * ****** *** ********** **** ******* ******* & *******.
  2. ***, **** : *** ******* * ********** **** **** ********* ** *** ***** ** ***** **** *** ***** *** ** ****** **** *** ******* ******** ** *******, ********* *** ********* **** ******* **** ** *** ***** ******* ****.***** ***** ** *** ********** ****** ************.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.